Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1994 Feb;70(2):84–89. doi: 10.1136/adc.70.2.84

Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.

L T Weaver 1, M R Green 1, K Nicholson 1, J Mills 1, M E Heeley 1, J A Kuzemko 1, S Austin 1, G A Gregory 1, A E Dux 1, J A Davis 1
PMCID: PMC1029705  PMID: 8129449

Abstract

All newborn infants in East Anglia are screened for cystic fibrosis by blood immunoreactive trypsin assay at 7 days. Thirty eight infants with cystic fibrosis were randomised to treatment with either continuous oral flucloxacillin 250 mg/day (group P, n = 18) or with episodic antimicrobials as clinically indicated (group E, n = 20). Their progress was monitored from diagnosis to 24 months by a nurse coordinator who visited all infants regularly, at home and in hospital, to collect anthropometric, dietary, clinical, and microbiological data. Mean (range) age of confirmation of diagnosis was 5.7 weeks (1-14 weeks). There was no significant difference in birth weight, genotype, immunoreactive trypsin concentration, neonatal history, symptoms at diagnosis, pancreatic enzyme supplementation, or parental smoking history between the groups. Infants in group E had more frequent cough and a greater number of Staphylococcus aureus isolates than infants in group P. More infants of group E were admitted to hospital, had higher admission rates during the second year (19 v 5), for longer periods (6.4 v 2.2 days), despite receiving more than double the number of courses of antibiotics than group P infants (in addition to flucloxacillin). Continuous prophylactic flucloxacillin from early diagnosis of cystic fibrosis is associated with improved clinical progress during the first two years of life.

Full text

PDF
84

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abman S. H., Ogle J. W., Harbeck R. J., Butler-Simon N., Hammond K. B., Accurso F. J. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr. 1991 Aug;119(2):211–217. doi: 10.1016/s0022-3476(05)80729-2. [DOI] [PubMed] [Google Scholar]
  2. Boland C., Thompson N. L. Effects of newborn screening of cystic fibrosis on reported maternal behaviour. Arch Dis Child. 1990 Nov;65(11):1240–1244. doi: 10.1136/adc.65.11.1240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chatfield S., Owen G., Ryley H. C., Williams J., Alfaham M., Goodchild M. C., Weller P. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child. 1991 Jan;66(1 Spec No):29–33. doi: 10.1136/adc.66.1_spec_no.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chrispin A. R., Norman A. P. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol. 1974;2(2):101–105. doi: 10.1007/BF01314939. [DOI] [PubMed] [Google Scholar]
  5. Cystic fibrosis in the United Kingdom 1977-85: an improving picture. British Paediatric Association Working Party on Cystic Fibrosis. BMJ. 1988 Dec 17;297(6663):1599–1602. doi: 10.1136/bmj.297.6663.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dankert-Roelse J. E., te Meerman G. J., Martijn A., ten Kate L. P., Knol K. Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. J Pediatr. 1989 Mar;114(3):362–367. doi: 10.1016/s0022-3476(89)80552-9. [DOI] [PubMed] [Google Scholar]
  7. Green M. R., Weaver L. T., Heeley A. F., Nicholson K., Kuzemko J. A., Barton D. E., McMahon R., Payne S. J., Austin S., Yates J. R. Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history. Arch Dis Child. 1993 Apr;68(4):464–467. doi: 10.1136/adc.68.4.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Greer R., Shepherd R., Cleghorn G., Bowling F. G., Holt T. Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis. J Pediatr Gastroenterol Nutr. 1991 Jul;13(1):52–58. doi: 10.1097/00005176-199107000-00010. [DOI] [PubMed] [Google Scholar]
  9. Heeley A. F., Heeley M. E., King D. N., Kuzemko J. A., Walsh M. P. Screening for cystic fibrosis by died blood spot trypsin assay. Arch Dis Child. 1982 Jan;57(1):18–21. [PMC free article] [PubMed] [Google Scholar]
  10. Kelly N. M., Falkiner F. R., Keane C. T. Acetamide broth for isolation of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 1983 Jan;17(1):159–159. doi: 10.1128/jcm.17.1.159-.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pier G. B. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis. 1985 Apr;151(4):575–580. doi: 10.1093/infdis/151.4.575. [DOI] [PubMed] [Google Scholar]
  12. Reardon M. C., Hammond K. B., Accurso F. J., Fisher C. D., McCabe E. R., Cotton E. K., Bowman C. M. Nutritional deficits exist before 2 months of age in some infants with cystic fibrosis identified by screening test. J Pediatr. 1984 Aug;105(2):271–274. doi: 10.1016/s0022-3476(84)80128-6. [DOI] [PubMed] [Google Scholar]
  13. Roberts G., Stanfield M., Black A., Redmond A. Screening for cystic fibrosis: a four year regional experience. Arch Dis Child. 1988 Dec;63(12):1438–1443. doi: 10.1136/adc.63.12.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
  15. Sokol R. J., Reardon M. C., Accurso F. J., Stall C., Narkewicz M., Abman S. H., Hammond K. B. Fat-soluble-vitamin status during the first year of life in infants with cystic fibrosis identified by screening of newborns. Am J Clin Nutr. 1989 Nov;50(5):1064–1071. doi: 10.1093/ajcn/50.5.1064. [DOI] [PubMed] [Google Scholar]
  16. Sorenson J. R., Levy H. L., Mangione T. W., Sepe S. J. Parental response to repeat testing of infants with 'false-positive' results in a newborn screening program. Pediatrics. 1984 Feb;73(2):183–187. [PubMed] [Google Scholar]
  17. Wesley A. W., Smith P. A., Elliott R. B. Experience with neonatal screening for cystic fibrosis in New Zealand using measurement of immunoreactive trypsinogen. Aust Paediatr J. 1989 Jun;25(3):151–155. doi: 10.1111/j.1440-1754.1989.tb01440.x. [DOI] [PubMed] [Google Scholar]
  18. Wilcken B., Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet. 1985 Dec 14;2(8468):1319–1321. doi: 10.1016/s0140-6736(85)92623-6. [DOI] [PubMed] [Google Scholar]
  19. Wilcken B., Towns S. J., Mellis C. M. Diagnostic delay in cystic fibrosis: lessons from newborn screening. Arch Dis Child. 1983 Nov;58(11):863–866. doi: 10.1136/adc.58.11.863. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES